

<b>Subject:</b>	Therapeutic Drug Monitoring for 5-Fluorouracil		
<b>Policy Number:</b>	PO-RE-133v1		
<b>Effective Date:</b>	05/01/2025	<b>Last Approval Date:</b>	03/17/2025

[Policy Description](#) | [Indications and/or Limitations of Coverage](#) | [Scientific Background](#) | [Applicable Codes](#) | [Related Policies](#) | [Reference Materials](#) | [Revision History](#) | [Disclaimer](#)

## I. Policy Description

Chemotherapeutic agents are incredibly potent drugs, often carrying cytotoxic side effects. Most chemotherapeutic drugs have a steep dose-response relationship and a narrow therapeutic index (a range where an agent provides therapeutic effect without major side effects). Identification of the optimal dose of a chemotherapeutic agent, such as 5-fluorouracil, has been proposed as a potential improvement for the management of cancer patients (Eaton, 2024).

This policy does not address pharmacogenetic testing to aid or direct chemotherapies. For pharmacogenetic testing, please refer to AHS-M2021.

### Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the “Applicable State and Federal Regulations” section of this policy document.

- For individuals who are undergoing 5-fluorouracil chemotherapy, therapeutic drug monitoring (TDM) to aid in managing dose adjustment **MEETS COVERAGE CRITERIA**.

*The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual’s illness.*

- To aid in managing dose adjustment for individuals undergoing 5-fluorouracil chemotherapy, the following tests **DO NOT MEET COVERAGE CRITERIA**:
  - Uracil breath tests.
  - Dihydrouracil/uracil ratio testing of plasma, serum, or urine samples.

### Scientific Background

Chemotherapeutic agents encompass a wide variety of medications used to treat cancer. However, due to their cytotoxicity, these agents often have debilitating side effects such as nausea, vomiting, and more. Therefore, it can be useful to identify an “optimal” dose of these agents (for an individual patient) maximize therapeutic efficacy and minimize harmful side effects. Numerous methods to identify an individual’s optimal dose exist, such as body surface area (BSA)-based dosing, weight-

based dosing, fixed-dose medications, and area-under-curve (AUC) dosing, which is generated by a curve of plasma concentration as a function of time. With both variables known, it would be possible to identify the exact amount of drug exposed to an individual instead of relying on clinical symptoms. AUC-based dosing is typically used for drugs cleared through glomerular filtration (such as carboplatin). However, AUC-based dosing is not usually applicable to most other anticancer agents as elimination of other drugs often involves several other pathways, thereby introducing additional variables that influence drug clearance (Eaton, 2024).

One common therapeutic agent is 5-fluorouracil, or 5-FU. Currently, 5-FU is administered intravenously as a continuous infusion; BSA-based dosage is often used to optimize treatment, and an AUC between 20 and 30 [mg×h×L] is recommended (Mindt et al., 2019). This particular chemotherapeutic agent can be used alone, or in a combinatory setting, to treat many types of cancer including breast, anal, stomach, colon, head, neck, and some skin cancers (Cancer Research, 2024). Therapeutic drug monitoring (TDM), known as “the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient’s bloodstream, thereby optimizing individual dosage regimens” (Kang & Lee, 2009), has shown promise in 5-FU based treatment regimens. In particular, the TDM practice has resulted in reduced toxicity and improved efficacy for the intravenous administration of 5-FU (Hashimoto et al., 2020).

### ***Proprietary Testing***

Proprietary tests have been developed for identification of the optimal dose of several chemotherapeutic agents. Saladax Biomedical, under the product umbrella termed MyCare, offers a series of tests that aim to find the optimal dose for various chemotherapeutic agents. Their current catalog includes tests for 5-FU (My5-FU), paclitaxel (MyPaclitaxel), docetaxel (MyDocetaxel), and imatinib (MyImatinib). MyCare states that these tests will be able to guide dosing for these agents and minimize toxicity with only a blood test (MyCare, 2024a, 2024b). The test is intended for patients receiving 5-FU chemotherapy through intravenous infusion. The test takes plasma near the end of the infusion cycle and is based on the scattered light principle. The amount of scattered light varies inversely with the amount of 5-FU present in the plasma sample. The limit of detection is estimated at 52 ng/mL and the limit of quantitation is estimated at 85 ng/mL. A validated dose adjustment algorithm incorporates the measurements of 5-FU in plasma and uses AUC to calculate subsequent doses (NICE, 2014).

Additional tests have been proposed to aid in dosing and measuring toxicity in individuals undergoing chemotherapy. Since the efficacy of 5-FU depends on the enzyme dihydropyrimidine dehydrogenase (DPD), the concentration of uracil has been proposed to evaluate pyrimidine, including 5-FU, catabolism. The uracil breath test measures the concentration of carbon dioxide, a pyrimidine metabolic product, after an individual has ingested radiolabeled uracil (Cunha-Junior et al., 2013; Ezzeldin et al., 2009).

### ***Analytical Validity***

Buchel et al. (2013) compared My5-FU to other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). A total of 247 plasma samples were measured. The Cobas Integra 800 was found to have a “proportional bias of 7% towards higher values measured with the My5-FU assay” compared to liquid chromatography-tandem mass spectrometry (LC-MS/MS). However, when Cobas Integra 800 was compared to the other three clinical analyzers, only a

proportional bias of  $\leq 1.6\%$  and a constant bias below the limit of detection was observed (Buchel et al., 2013).

### ***Clinical Utility and Validity***

Yang et al. (2016) conducted a meta-analysis of data from two randomized control trials (RCTs) and three observational studies (654 patients) to compare the efficacy and toxicity of the use of pharmacokinetic (PK)-guided versus Body Surface Area (BSA)-based dose adjustment of 5-FU in advanced cancers. PK-monitored 5-FU therapy was found to be associated with “significant improvement in overall response rate (odds ratio = 2.04) compared with the traditional BSA method.” The researchers concluded that “in comparison with conventional BSA method, PK-based 5-FU dosage confirmed a superior overall response rate and improved toxicities irrespective of significant difference, the results of which indicated that PK-monitored 5-FU dosage has the potential to be performed in colorectal cancer personalized therapy” (Yang et al., 2016).

Fang et al. (2016) performed a meta-analysis to compare the BSA-based algorithm to a pharmacokinetic (PKG)-based algorithm for 5-fluorouracil (5-FU). Four studies (n = 504) were included. The authors found that the PKG algorithm “significantly” improved the objective response rate of 5-FU chemotherapy compared to the BSA-based algorithm. PKG was also found to “markedly” decrease the risk of grade 3/4 adverse drug reactions (Fang et al., 2016). Likewise, another study comparing 5-FU TDM to BSA-guided dosing results in patients with gastrointestinal cancer (n = 155) also reports greater interpersonal variability when using a BSA-guided strategy as compared to TDM (Morawska et al., 2018). A third study demonstrates that TDM can result in even greater improvements in elderly gastrointestinal cancer patients (older than 75 years old) as compared to younger patients (71% improvement in AUC vs. 50% improvement, respectively). This is significant considering that the majority of previous clinical trials excluded elderly patients (Macaire et al., 2019).

Wilhelm et al. (2016) evaluated the use of TDM to personalize 5-FU dosing in patients with colorectal cancer. Seventy-five patients were included. The authors aimed to achieve a target AUC of 20-30 mg x h/L and adjusted each cycle of 5-FU accordingly. The average AUC of 5-FU on the initial administration was “ $18 \pm 6$  mg x h/L, with 64%, 33%, and 3% of the patients below, within, or above the target AUC range, respectively.” By the fourth administration, the average 5-FU AUC was  $25 \pm 7$  mg x h/L, with 54% of patients within the target 5-FU AUC range. The incidence of 5-FU related side effects was reduced compared to historical data despite the increased dose. The authors concluded that “personalization of 5-FU dosing using TDM in routine clinical practice resulted in significantly improved 5-FU exposure and suggested a lower incidence of 5-FU-related toxicities” (Wilhelm et al., 2016).

Gamelin et al. (2008) conducted a study to compare conventional dosing of fluorouracil (FU) with pharmacokinetically guided FU dose adjustment in terms of response, tolerability, and survival. A total of 208 patients with measurable metastatic colorectal cancer were randomly assigned to two groups: group A (104 patients; 96 assessable), in which the FU dose was calculated based on body-surface area; and group B (104 patients; 90 assessable), in which the FU dose was individually determined using pharmacokinetically guided adjustments. Patients that received FU dose adjustment based on pharmacokinetic monitoring showed significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities. The researchers concluded that “these results support the value of pharmacokinetically guided management of FU dose in the treatment of metastatic colorectal patients” (Gamelin et al., 2008).

Engels et al. (2011) examined the effect of pharmacokinetic (PK)-guided docetaxel dosing on interindividual variability in exposure. AUC was used to guide dosing, and 15 patients were included. The authors found that variability (standard deviation) decreased by 35% after one course of PK-guided dosing. However, the authors stated further research was needed (Engels et al., 2011).

Joerger et al. (2007) built a pharmacokinetic-pharmacodynamic model of paclitaxel/carboplatin in ovarian cancer patients. Time above paclitaxel plasma concentration of 0.05 to 0.2  $\mu\text{mol/L}$  ( $t_c > 0.05\text{--}0.2 \mu\text{mol/L}$ ) is thought to be a good predictive marker for severe neutropenia and overall clinical outcome. A total of 139 patients were included in the study; each participant was given “175 mg/m<sup>2</sup> over 3 hours followed by carboplatin area under the concentration-time curve 5 mg/mL\*min over 30 min.” In 34 patients with measurable disease, objective response rate was 76%. Paclitaxel  $t_c > 0.05 \mu\text{mol/L}$  was found to be significantly higher in patients with a complete ( $t = 91.8$  hours) or partial response ( $t = 76.3$ ) compared to patients with progressive disease ( $t = 31.5$ ). Paclitaxel  $t_c$  was also found to predict severe neutropenia well (Joerger et al., 2007).

A 2017 study by Moeung et al. (2017) evaluated the efficacy of TDM in patients ( $n = 89$ ) with advanced germ cell tumors who receive high dose chemotherapy (TI-CE) as compared to using a formula-based covariate equation dosing method. The metric used to assess the efficacy of these two approaches was AUC for carboplatin. TDM was used on 58 of the patients for three days “to develop a covariate equation for carboplatin clearance prediction adapted for future TI-CE patients, and its performance was prospectively evaluated on the other 29 patients along with different methods of carboplatin clearance prediction.” Using the developed covariate equation to determine dosing, the researchers showed that the mean AUC was 24.4 mg.min/ml per cycle with 10<sup>th</sup> and 90<sup>th</sup> percentiles of 22.4 and 26.8, respectively. They conclude, “TDM allows controlling and reaching the target AUC.” An alternative is using “the new equation of carboplatin clearance prediction,” a strategy better adapted for young individual patients when TDM cannot be used (Moeung et al., 2017). However, more recent studies have also shown that the method to determine carboplatin clearance (for example, glomerular filtration rate (GFR) versus estimated creatinine clearance (CrCl)) can have a significant effect on determining the actual AUC for carboplatin (Morrow et al., 2019).

Guilhot et al. (2012) evaluated the correlation between “imatinib trough plasma concentrations ( $C_{\text{min}}$ ) and clinical response and safety in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the Tyrosine Kinase Inhibitor OPTimization and Selectivity (TOPS) trial.” Patients were randomized to 400 mg/day or 800 mg/day of imatinib. The authors found that the  $C_{\text{min}}$  was stable for patients in the 400 mg/day cohort but showed a slight decrease in the 800 mg/day cohort due to dose adjustments. The rates of major molecular response (MMR) and complete cytogenetic response (CCyR) was found to be significantly lower in patients under the twenty fifth percentile of  $C_{\text{min}}$  (1165 ng/mL). The authors also observed an association between high imatinib  $C_{\text{min}}$  and side effects such as edema (Guilhot et al., 2012).

Freeman et al. (2015) evaluated the clinical and cost effectiveness of the My5-FU assay. The authors compared the assay to gold standards of serum testing and chemotherapeutic dosing. Thirty-five studies regarding clinical effectiveness and 54 studies regarding cost effectiveness were identified. The investigators identified a high “apparent” correlation between My5-FU, high-performance liquid chromatography (HPLC), and liquid chromatography-mass spectrometry (LC-MS), although upper and lower limits of agreement ranged from -18% and 30%. Median overall survival (OS) was found to be 19.6 months for pharmacokinetic dosing (PK) compared to 14.6 months for body surface area (BSA)-guided dosing of 5-FU plus folinic acid. The authors also built a cost-effectiveness model for

the My5-FU assay for metastatic colorectal cancer and head and neck cancer. The model showed My5-FU to be 100% cost effective at £20,000 per quality-adjusted life-year for both types, although the head and neck cancer was only an estimate. Despite these findings, the authors noted that “considerable uncertainties remain about evidence quality and practical implementation” (Freeman et al., 2015).

Cunha-Junior et al. (2013) studied the use of the uracil breath test to determine 5-FU toxicity in gastrointestinal cancer patients (n = 33). Their results show that the uracil breath test had a sensitivity and specificity of 61.5% and 85%, respectively in distinguishing individuals with grade 3-4 versus grade 0-1 toxicity. Likewise, the sensitivity and specificity of distinguishing DPD-deficiency versus non-DPD-deficiency are 75% and 85%, respectively. The authors conclude that the uracil breath test “has moderate accuracy in discriminating individuals who manifested severe toxicity from those who had mild or no toxicity to 5FU” (Cunha-Junior et al., 2013).

Macaire et al. (2019) researched the effects of TDM to optimize 5-FU chemotherapy in gastrointestinal cancer patients under and over 75 years of age. A total of 154 participants with gastrointestinal cancer participated in this study; thirty-one participants were older than 75 years of age. “At cycle 1 (C1), the 5-FU dose was calculated using patient's body surface area, then a blood sample was drawn to measure 5-FU concentration and 5-FU dose was adjusted at the subsequent cycles based on C1 concentration. Assessments of toxicity were performed at the beginning of every cycle” (Macaire et al., 2019). Results show that approximately 71% of patients older than 75 years of age required dose adjustments after C1, while only 50% of younger patients required adjustments. Further, after dose adjustments, by cycle 3 (C3), the percentage of patients above age 75 with severe 5-FU related toxicity fell from 15% to 5%. The authors conclude that “Pharmacokinetic-guided 5-FU-dosing algorithm, leading to an improved tolerability while remaining within therapeutic concentration range, is even more valuable for patients older than 75 years than in younger patients” (Macaire et al., 2019).

Deng et al. (2020) studied the efficacy of pharmacokinetic-based 5-FU dosing management in advanced colorectal cancer patients. A total of 153 patients with advanced colorectal cancer were randomized to receive a double-week chemotherapy with 5-FU using pharmacokinetic dosing or 5-FU chemotherapy with BSA guided dosing. In the first four weeks of treatment, patients in the experimental group were administered 5-FU according to the classic strategy of body surface area dosing before transitioning into pharmacokinetic AUC-based dosing. For the duration of the study, all patients in the control group continued with BSA guided chemotherapy. The efficacy, toxic side effects, and survival rate were assessed throughout the study. In the AUC-based dosing (experimental) group, “the rate of diarrhea significantly decreased (37.50% vs. 70.00%, P=0.010), and incidence of oral mucositis reduced (54.17% vs. 82.50%, P=0.014). Compared with the control group, the clinical benefit rate of experimental group was much higher (90.79% vs. 79.22%, P=0.046).” There was no significant difference in other 5-FU related toxic side effects such as nausea or vomiting and no difference in progression-free survival between the two groups. The authors concluded that “pharmacokinetic- based dose management of 5-Fluorouracil reduces the toxicity of chemotherapy and improves long-term efficacy of chemotherapy for advanced colorectal cancer patients” (Deng et al., 2020).

Dolat et al. (2020) studied how evaluating DPD deficiency before initiating 5-FU treatment could help limit 5-FU toxicity by investigating the relationship between 5-FU clearance and DPD activity markers. There were 169 patients with colorectal, pancreas, and metastatic cancer included in the study and the DPD marker, uracilemia (U), was measured. Overall, all patients benefited from a pre-therapeutic

DPYD genotyping and phenotyping. There was no correlation between uracilemia levels and 5-FU clearance. However, in patients with low DPD marker levels ( $U < 16$  ng/mL), 5-FU exposure was higher than in other patients and these patients benefited from an increase in dose following 5-FU therapeutic drug monitoring (TDM). The author states that if guidelines recommend decreasing the 5-FU dose in patients with  $U > 16$  ng/mL, then these patients are at risk of under-exposure and 5-FU TDM should be conducted to avoid loss of efficacy (Dolat et al., 2020).

Vithanachchi et al. (2021) reviewed the economic evaluations of TDM interventions for certain cancer drugs. Through identifying 11 publications, the researchers found that TDM with imatinib and TDM with 5-FU were the “most commonly assessed interventions.” Using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Checklist, they evaluated the quality of reporting of economic evaluations, and found that these publications met 61-91% of CHEERS checklist criteria. Additionally, “all publications considered TDM to be cost-effective based on an incremental cost-effectiveness ratio below the willingness to pay threshold (64%) or being cost-saving (36%),” and TDM interventions were likely to be “cost-effective in an oncology landscape where treatments offering small benefits have high cost.” To fully evaluate the impact of TDM, the researchers also suggest assessing uncertainties in the clinical evidence for newer treatments used alongside or after TDM treatment. This research elucidated the context by which TDM could be beneficial fiscally and how that may impact future care.

Laures et al. (2022) investigated DPD deficiency screening using uracil-based phenotyping to see whether it reduced the negative side effects of 5-Fluorouracil-based chemotherapy. French recommendations call for screening for DPD deficiency (through plasma uracil quantification) before instituting fluoropyrimidine-based chemotherapy. A total of 198 patients who received 5-FU therapy (these participants had DPD deficiency) were compared to 94 reference patients. According to the authors, the study showed a reduction in 5-FU serious toxic events during the first four courses of chemotherapy. Their analysis “identified a significant difference in adverse effects toxicity coupled with their frequency between patients with an identified DPD phenotype and patients with an unknown DPD phenotype.” However, the authors also described how various studies of DPD deficiency have given conflicting results. For example, a separate study “demonstrated no significant difference in the prevalence of toxicities between DPD-deficient and non-deficient patients, suggesting that further work is needed to investigate the association of phenotyping with toxicity” (Laures et al., 2022; Tejedor-Tejada et al., 2022)

## **Guidelines and Recommendations**

### **International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)**

The IATDMCT released guidelines on the dosing of 5-FU. With regards to assessing systemic exposure to 5-FU, the IATDMCT noted that area-under-curve (AUC) was the “accepted and clinically relevant” metric. They also noted that a relationship existed between 5-FU AUC and clinical activity (as well as toxicity). They go on to state, “It should be noted that statistically significant correlations between 5-FU exposure and toxicity have been observed across several disease types (squamous cell carcinoma of the head and neck (SCCHYN), nasopharyngeal cancer, and CRC), disease settings (metastatic, locally advanced), and dosing types (bolus, infusion).” Also, they note that “several clinical studies... have found statistically significant correlations between 5-FU exposure and clinical outcome, mostly with response rates being the metric, but also indicated by overall survival” (Beumer et al., 2019; NICE, 2014).

The IATDMCT also made remarks on the use of TDM for 5-FU. They noted that TDM reduced variability and toxicity, as well as improved clinical activity in patients receiving 5-FU, and “strongly recommend” TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens (Beumer et al., 2019).

Concerning the use of the uracil breath test, the IATDMCT states, “The uracil breath test does not help in determining the correct dose and is not recommended for clinical use” (Beumer et al., 2019).

### **National Comprehensive Cancer Network (NCCN)**

The NCCN published guidelines on management of antiemesis, intended to control one of chemotherapy’s primary side effects. In it, the only chemotherapeutic agent listed with an AUC-based dosing regimen is carboplatin. Docetaxel, 5-FU and paclitaxel are listed as having 10-30% emetic risk whereas imatinib  $\leq 400$  mg/day is listed as  $<30\%$  risk. No information regarding therapeutic drug monitoring was included (NCCN, 2024a). Furthermore, the NCCN did not address TDM in either its colon cancer or head and neck cancer guidelines (NCCN, 2024b, 2024c).

### **National Institute for Health and Care Excellence (NICE)**

The NICE remarked that the My5-FU assay should only be recommended for research purposes, although they noted that it has “promise” (NICE, 2014). In a December 2017 review of the 2014 guideline, NICE stated that no changes were required (NICE, 2017).

### **Clinical Pharmacogenetics Implementation Consortium (CPIC)**

In 2017, the CPIC published updated guidance on dihydropyrimidine dehydrogenase (*DPYD*) genotyping and fluoropyrimidine (5-FU) dosing. The following recommendations are related to TDM:

- “In *DPYD* poor metabolizers (*DPYD*-AS: 0.5 or 0), it is strongly recommended to avoid use of 5-fluorouracil containing regimens. However, if no fluoropyrimidine-free regimens are considered a suitable therapeutic option, 5-fluorouracil administration at a strongly reduced dose combined with early therapeutic drug monitoring may be considered for patients with *DPYD*-AS of 0.5. It should be noted, however, that no reports of the successful administration of low dose 5-fluorouracil in *DPYD* poor metabolizers are available to date.”
- “Pharmacokinetically-guided dosing of 5-fluorouracil has been shown to result in an increase in the proportion of patients with 5-fluorouracil exposure (AUC) within the targeted therapeutic range and a reduced number of 5-fluorouracil related adverse effects. In particular, to avoid underdosing of patients with genotype-based dose reductions who tolerate higher 5-fluorouracil doses, follow-up therapeutic drug monitoring is recommended.”
- For *DPYD* intermediate metabolizers, the following dosing recommendation was given: “Reduce starting dose based on activity score followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).”
- For *DPYD* poor metabolizers, the following dosing recommendation was given: “In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring” (Amstutz et al., 2018).

**Therapeutic Pharmacological Monitoring and Personalization of Treatments (STP-PT) Group of The French Society of Pharmacology and Therapeutics (SFPT) and the Groupe de Pharmacologie Clinique Oncologique (GPCO)**

The STP-PT group of the SFPT and GPCO on 5-FU therapeutic drug monitoring state that “based on the latest and most up-to-date literature data, [we] recommend the implementation of 5-FU Therapeutic Drug Monitoring in order to ensure an adequate 5-FU exposure” (Lemaitre et al., 2018).

**Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER**

Etienne-Grimaldi et al. (2023) released “Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency [DPD],” which included recommendations for FP-based chemotherapy. The guideline recommends the following:

- “EMA recommends DPD testing (*DPYD* variants or uracilemia) before FP-based chemotherapy.
- Genotyping relevance of the 4 consensual *DPYD* variants is restricted to Caucasians.
- *DPYD* genotype-guided FP dose reduction is clinically validated, contrary to uracilemia.
- Impact of DPD-guided FP dose reduction on efficacy needs further investigation.
- 5FU therapeutic drug monitoring is recommended in partial DPD-deficient patients” (Etienne-Grimaldi et al., 2023).

**Food and Drug Administration (FDA)**

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

The FDA’s “Prescribing Information” documents for fluorouracil, paclitaxel, imatinib, and docetaxel do not include AUC as a method to adjust dosage (FDA, 2016a, 2016b, 2018, 2021).

**II. Applicable Codes**

Code	Description	Comment
S3722	Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil	
80299	Quantitation of therapeutic drug, not elsewhere specified	
82542	Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	
83789	Mass spectrometry and tandem mass spectrometry (eg, MS,	



	MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	
--	--	--

Current Procedural Terminology © American Medical Association. All Rights reserved.

*Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.*

### III. Definitions

Term	Meaning

### IV. Related Policies

Policy Number	Policy Description
N/A	N/A

Current Procedural Terminology © American Medical Association. All rights reserved.

*Procedure codes appearing in Reimbursement Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.*

### V. Reference Materials

<p>Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., &amp; Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clin Pharmacol Ther</i>, 103(2), 210-216.  <a href="https://doi.org/10.1002/cpt.911">https://doi.org/10.1002/cpt.911</a></p>
<p>Beumer, J. H., Chu, E., Allegra, C., Tanigawara, Y., Milano, G., Diasio, R., Kim, T. W., Mathijssen, R. H., Zhang, L., Arnold, D., Muneoka, K., Boku, N., &amp; Joerger, M. (2019). Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. <i>Clin Pharmacol Ther</i>, 105(3), 598-613.  <a href="https://doi.org/10.1002/cpt.1124">https://doi.org/10.1002/cpt.1124</a></p>
<p>Buchel, B., Sistonen, J., Joerger, M., Aebi, Y., Schurch, S., &amp; Largiader, C. R. (2013). Comparative evaluation of the My5-FU immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels</p>

<p>in cancer patients. <i>Clin Chem Lab Med</i>, 51(8), 1681-1688. <a href="https://doi.org/10.1515/cclm-2012-0641">https://doi.org/10.1515/cclm-2012-0641</a></p>
<p>Cancer Research. (2024, July 26, 2024). <i>Fluorouracil (5FU)</i>. <a href="https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/fluorouracil">https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/fluorouracil</a></p>
<p>Cunha-Junior, G. F., De Marco, L., Bastos-Rodrigues, L., Bolina, M. B., Martins, F. L., Pianetti, G. A., Cesar, I. C., &amp; Coelho, L. G. (2013). (13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients. <i>Cancer Chemother Pharmacol</i>, 72(6), 1273-1282. <a href="https://doi.org/10.1007/s00280-013-2309-4">https://doi.org/10.1007/s00280-013-2309-4</a></p>
<p>Deng, R., Shi, L., Zhu, W., Wang, M., Guan, X., Yang, D., &amp; Shen, B. (2020). Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment. <i>Mini Rev Med Chem</i>, 20(2), 161-167. <a href="https://doi.org/10.2174/1389557519666191011154923">https://doi.org/10.2174/1389557519666191011154923</a></p>
<p>Dolat, M., Macaire, P., Goirand, F., Vincent, J., Hennequin, A., Palmier, R., Bengrine-Lefevre, L., Ghiringhelli, F., Royer, B., &amp; Schmitt, A. (2020). Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure. <i>Pharmaceuticals (Basel)</i>, 13(11). <a href="https://doi.org/10.3390/ph13110416">https://doi.org/10.3390/ph13110416</a></p>
<p>Eaton, K., Lyman, Gary. (2024, August 19). <i>Dosing of anticancer agents in adults</i>. <a href="https://www.uptodate.com/contents/dosing-of-anticancer-agents-in-adults">https://www.uptodate.com/contents/dosing-of-anticancer-agents-in-adults</a></p>
<p>Engels, F. K., Loos, W. J., van der Bol, J. M., de Bruijn, P., Mathijssen, R. H. J., Verweij, J., &amp; Mathot, R. A. A. (2011). Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study. <i>Clinical Cancer Research</i>, 17(2), 353. <a href="https://doi.org/10.1158/1078-0432.CCR-10-1636">https://doi.org/10.1158/1078-0432.CCR-10-1636</a></p>
<p>Etienne-Grimaldi, M.-C., Pallet, N., Boige, V., Ciccolini, J., Chouchana, L., Barin-Le Guellec, C., Zaanani, A., Narjoz, C., Taieb, J., Thomas, F., &amp; Lorient, M.-A. (2023). Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. <i>European Journal of Cancer</i>, 181, 3-17. <a href="https://doi.org/10.1016/j.ejca.2022.11.028">https://doi.org/10.1016/j.ejca.2022.11.028</a></p>
<p>Ezzeldin, H. H., Acosta, E. P., Mattison, L. K., Fourie, J., Modak, A., &amp; Diasio, R. B. (2009). (13)C-5-FU breath test current status and future directions: a comprehensive review. <i>J Breath Res</i>, 3(4), 047002. <a href="https://doi.org/10.1088/1752-7155/3/4/047002">https://doi.org/10.1088/1752-7155/3/4/047002</a></p>
<p>Fang, L., Xin, W., Ding, H., Zhang, Y., Zhong, L., Luo, H., Li, J., Yang, Y., &amp; Huang, P. (2016). Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis. <i>Sci Rep</i>, 6, 25913. <a href="https://doi.org/10.1038/srep25913">https://doi.org/10.1038/srep25913</a></p>
<p>FDA. (2016a). <i>GLEEVEC (imatinib mesylate) tablets for oral use</i> <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf</a></p>
<p>FDA. (2016b). <i>Label for NDA 012209 FLUOROURACIL</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf</a></p>
<p>FDA. (2018). <i>ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)</i> <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021660s045lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021660s045lbl.pdf</a></p>
<p>FDA. (2021). <i>Docetaxel Injection, Solution for Intravenous Infusion</i>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205934s003lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205934s003lbl.pdf</a></p>
<p>Freeman, K., Connock, M., Cummins, E., Gurung, T., Taylor-Phillips, S., Court, R., Saunders, M., Clarke, A., &amp; Sutcliffe, P. (2015). Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. <i>Health Technol Assess</i>, 19(91), 1-321, v-vi. <a href="https://doi.org/10.3310/hta19910">https://doi.org/10.3310/hta19910</a></p>
<p>Gamelin, E., Delva, R., Jacob, J., Merrouche, Y., Raoul, J. L., Pezet, D., Dorval, E., Piot, G., Morel, A., &amp; Boisdron-Celle, M. (2008). Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients</p>

with metastatic colorectal cancer. <i>J Clin Oncol</i> , 26(13), 2099-2105. <a href="https://doi.org/10.1200/jco.2007.13.3934">https://doi.org/10.1200/jco.2007.13.3934</a>
Guilhot, F., Hughes, T. P., Cortes, J., Druker, B. J., Baccharani, M., Gathmann, I., Hayes, M., Granvil, C., & Wang, Y. (2012). Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. <i>Haematologica</i> , 97(5), 731. <a href="https://doi.org/10.3324/haematol.2011.045666">https://doi.org/10.3324/haematol.2011.045666</a>
Hashimoto, Y., Yoshida, Y., Yamada, T., Aisu, N., Yoshimatsu, G., Yoshimura, F., & Hasegawa, S. (2020). Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs. <i>Anticancer Res</i> , 40(8), 4655-4661. <a href="https://doi.org/10.21873/anticancer.14464">https://doi.org/10.21873/anticancer.14464</a>
Joerger, M., Huitema, A. D. R., Richel, D. J., Dittrich, C., Pavlidis, N., Briasoulis, E., Vermorken, J. B., Strocchi, E., Martoni, A., Sorio, R., Sleeboom, H. P., Izquierdo, M. A., Jodrell, D. I., Calvert, H., Boddy, A. V., Hollema, H., Féty, R., Van der Vijgh, W. J. F., Hempel, G., . . . Schellens, J. H. M. (2007). Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. <i>Clinical Cancer Research</i> , 13(21), 6410. <a href="https://doi.org/10.1158/1078-0432.CCR-07-0064">https://doi.org/10.1158/1078-0432.CCR-07-0064</a>
Kang, J. S., & Lee, M. H. (2009). Overview of therapeutic drug monitoring. <i>Korean J Intern Med</i> , 24(1), 1-10. <a href="https://doi.org/10.3904/kjim.2009.24.1.1">https://doi.org/10.3904/kjim.2009.24.1.1</a>
Laures, N., Konecki, C., Brugel, M., Giffard, A.-L., Abdelli, N., Botsen, D., Carlier, C., Gozalo, C., Feliu, C., Slimano, F., Djerada, Z., & Bouché, O. (2022). Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis. <i>Pharmaceutics</i> , 14(10), 2119. <a href="https://doi.org/10.3390/pharmaceutics14102119">https://doi.org/10.3390/pharmaceutics14102119</a>
Lemaitre, F., Goirand, F., Launay, M., Chatelut, E., Boyer, J. C., Evrard, A., Paludetto, M. N., Guilhaumou, R., Ciccolini, J., & Schmitt, A. (2018). [5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer]. <i>Bull Cancer</i> , 105(9), 790-803. <a href="https://doi.org/10.1016/j.bulcan.2018.06.008">https://doi.org/10.1016/j.bulcan.2018.06.008</a> (Suivi thérapeutique pharmacologique du 5-fluorouracile : mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer.)
Macaire, P., Morawska, K., Vincent, J., Quipourt, V., Marilier, S., Ghiringhelli, F., Bengrine-Lefevre, L., & Schmitt, A. (2019). Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years. <i>Eur J Cancer</i> , 111, 116-125. <a href="https://doi.org/10.1016/j.ejca.2019.01.102">https://doi.org/10.1016/j.ejca.2019.01.102</a>
Mindt, S., Aida, S., Merx, K., Müller, A., Gutting, T., Hedtke, M., Neumaier, M., & Hofheinz, R. D. (2019). Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects. <i>Clin Chem Lab Med</i> , 57(7), 1012-1016. <a href="https://doi.org/10.1515/ccim-2018-1177">https://doi.org/10.1515/ccim-2018-1177</a>
Moeung, S., Chevreau, C., Broutin, S., Guitton, J., Lelievre, B., Ciccolini, J., Massart, C., Flechon, A., Delva, R., Gravis, G., Lotz, J. P., Bay, J. O., Gross-Goupil, M., Paci, A., Marsili, S., Malard, L., Chatelut, E., & Thomas, F. (2017). Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. <i>Clin Cancer Res</i> , 23(23), 7171-7179. <a href="https://doi.org/10.1158/1078-0432.Ccr-17-1344">https://doi.org/10.1158/1078-0432.Ccr-17-1344</a>
Morawska, K., Goirand, F., Marceau, L., Devaux, M., Cueff, A., Bertaut, A., Vincent, J., Bengrine-Lefevre, L., Ghiringhelli, F., & Schmitt, A. (2018). 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. <i>Oncotarget</i> , 9(14), 11559-11571. <a href="https://doi.org/10.18632/oncotarget.24338">https://doi.org/10.18632/oncotarget.24338</a>
Morrow, A., Garland, C., Yang, F., De Luna, M., & Herrington, J. D. (2019). Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review. <i>J Oncol Pharm Pract</i> , 25(7), 1651-1657. <a href="https://doi.org/10.1177/1078155218805136">https://doi.org/10.1177/1078155218805136</a>

MyCare. (2024a). Clinical Studies. <a href="https://mycaretests.com/oncology/clinicians/#process">https://mycaretests.com/oncology/clinicians/#process</a>
MyCare. (2024b). You're not getting chemo the right way. <a href="https://mycaretests.com/oncology/">https://mycaretests.com/oncology/</a>
NCCN. (2024a, September 27, 2024). <i>NCCN Clinical Practice Guidelines in Oncology - Antiemesis Version 1.2024</i> . <a href="https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf">https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf</a>
NCCN. (2024b, August 22, 2024). <i>NCCN Clinical Practice Guidelines in Oncology - Colon Cancer Version 5.2024</i> . <a href="https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf">https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</a>
NCCN. (2024c, May 1, 2024). <i>NCCN Clinical Practice Guidelines in Oncology - Head and Neck Cancers Version 4.2024</i> . <a href="https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf">https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf</a>
NICE. (2014). Fluorouracil chemotherapy: The My5-FU assay for guiding dose adjustment. <a href="https://www.nice.org.uk/guidance/dg16">https://www.nice.org.uk/guidance/dg16</a>
NICE. (2017). Review of DG16: Fluorouracil chemotherapy: The My5-FU assay for guiding dose adjustment. <a href="https://www.nice.org.uk/guidance/dg16/evidence/review-decision-february-2018-pdf-4777017085">https://www.nice.org.uk/guidance/dg16/evidence/review-decision-february-2018-pdf-4777017085</a>
Tejedor-Tejada, E., Calvo, D. R., & Andreo, A. G. (2022). Determination of plasma uracil as a screening for dihydropyrimidine dehydrogenase deficiency: clinical application in oncological treatments. <i>European Journal of Hospital Pharmacy</i> , ejhpharm-2021-003210. <a href="https://doi.org/10.1136/ejhpharm-2021-003210">https://doi.org/10.1136/ejhpharm-2021-003210</a>
Vithanachchi, D. T., Maujean, A., Downes, M. J., & Scuffham, P. (2021). A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments. <i>Br J Clin Pharmacol</i> , 87(2), 271-283. <a href="https://doi.org/10.1111/bcp.14494">https://doi.org/10.1111/bcp.14494</a>
Wilhelm, M., Mueller, L., Miller, M. C., Link, K., Holdenrieder, S., Bertsch, T., Kunzmann, V., Stoetzer, O. J., Suttmann, I., Braess, J., Birkmann, J., Roessler, M., Moritz, B., Kraff, S., Salamone, S. J., & Jaehde, U. (2016). Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. <i>Clinical Colorectal Cancer</i> , 15(4), 381-388. <a href="https://doi.org/10.1016/j.clcc.2016.04.001">https://doi.org/10.1016/j.clcc.2016.04.001</a>
Yang, R., Zhang, Y., Zhou, H., Zhang, P., Yang, P., Tong, Q., Lyu, Y., & Han, Y. (2016). Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis. <i>Ther Drug Monit</i> , 38(1), 79-86. <a href="https://doi.org/10.1097/ftd.0000000000000238">https://doi.org/10.1097/ftd.0000000000000238</a>

## VI. Revision History

Revision Date	Summary of Changes
12/04/2024	Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review did not necessitate any modification to the coverage criteria.

### Disclaimer

Healthfirst's claim edits follow national industry standards aligned with CMS standards that include, but are not limited to, the National Correct Coding Initiative (NCCI), the National and Local Coverage Determination (NCD/LCD) policies, appropriate modifier usage, global surgery and multiple procedure reduction rules, medically unlikely edits, duplicates, etc. In addition, Healthfirst's coding edits incorporate industry-accepted AMA and CMS CPT, HCPCS and ICD-10 coding principles, National Uniform Billing Editor's revenue coding guidelines, CPT Assistant guidelines, New York



State-specific coding, billing, and payment policies, as well as national physician specialty academy guidelines (coding and clinical). Failure to follow proper coding, billing, and/or reimbursement policy guidelines could result in the denial and/or recoupment of the claim payment.

This policy is intended to serve as a resource for providers to use in understanding reimbursement guidelines for professional and institutional claims. This information is accurate and current as of the date of publication. It provides information from industry sources about proper coding practice. However, this document does not represent or guarantee that Healthfirst will cover and/or pay for services outlined. Reimbursement decisions are based on the terms of the applicable evidence of coverage, state and federal requirements or mandates, and the provider's participation agreement. This includes the determination of any amounts that Healthfirst or the member owes the provider.